Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New therapeutic approaches

S B Hanauer1, M I Schulman

  • 1University of Chicago Medical Center, Illinois, USA.

Gastroenterology Clinics of North America
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

The evolution of inflammatory bowel disease (IBD) treatments from older drugs to newer therapies necessitates understanding the core mechanisms driving inflammation. Further research is crucial for developing innovative treatments to enhance patient quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Alimentary pharmacology & therapeutics·2018
Same author

Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).

Alimentary pharmacology & therapeutics·2018
Same author

Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.

Alimentary pharmacology & therapeutics·2017
Same author

Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.

Alimentary pharmacology & therapeutics·2013
Same author

Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.

Alimentary pharmacology & therapeutics·2013
Same author

Treatment of perianal Crohn's disease: a medical approach.

Inflammatory bowel diseases·2013
Same journal

Living Donor Intestinal and Liver Transplantation.

Gastroenterology clinics of North America·2026
Same journal

Living Abdominal Organ Donation: A Plan B That Saves Lives.

Gastroenterology clinics of North America·2026
Same journal

Long-Term Outcomes of Living Liver Donors.

Gastroenterology clinics of North America·2026
Same journal

Perioperative Management of Living Liver Donor Patients.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Transplantation for Colorectal Cancer Liver Metastasis.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Graft in Adult Populations: Donor Selection and Workup.

Gastroenterology clinics of North America·2026
See all related articles

Area of Science:

  • Gastroenterology and Immunology
  • Pharmacology

Background:

  • Current treatments for inflammatory bowel disease (IBD) have evolved from sulfasalazine and hydrocortisone to aminosalicylates and steroids.
  • There is a need to clarify the primary events that activate or fail to down-regulate inflammatory cascades in IBD.
  • Advances in basic research offer promise for understanding IBD pathogenesis.

Purpose of the Study:

  • To review the evolution of IBD treatments.
  • To highlight the need for understanding the fundamental mechanisms of inflammation in IBD.
  • To emphasize the potential of ongoing research and clinical trials in developing novel therapies.

Main Methods:

  • Review of existing literature on IBD treatments.
  • Discussion of the transition from traditional to alternative therapies.

Related Experiment Videos

  • Analysis of the role of "nonspecific" anti-immunoinflammatory compounds.

    • Main Results:

    • The evolution of IBD pharmacotherapy from older agents to newer alternatives has been observed.
    • Clarification of primary inflammatory events in IBD is required.
    • Basic research advances are providing insights into IBD.

    Conclusions:

    • Continued investigation into the primary mechanisms of inflammation and its regulation is essential for IBD.
    • Novel therapeutic strategies are expected to emerge from the synergy between basic research and clinical observations.
    • Improving the quality of life for IBD patients remains a key objective.